SCHEMBL19475592

SCHEMBL19475592

CN(C)c1c(Cl)cc(Cl)cc1CN

nearest known ligand 0.34

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
PNMT P11086 2/20 0.34
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 1/20 0.33
GLA P06280 1/20 0.33
GAA P10253 1/20 0.33
HPGD P15428 1/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 1/20 0.33
PRMT1 Q99873 1/20 0.32
PYCR1 P32322 1/20 0.31
DPP4 P27487 1/20 0.31
POLB P06746 1/20 0.30
KRAS P01116 1/20 0.30
CYP2A6 P11509 1/20 0.30
HSP90AA1 P07900 1/20 0.30
CYP3A4 P08684 1/20 0.30
TSHR P16473 1/20 0.30
RECQL P46063 1/20 0.30
HSD17B10 Q99714 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2091395 0.78 ALDH1A1 (0.45) ALDH1A1KDM4EGAAHPGDPOLB
SCHEMBL10097951 0.72 CSNK2A1 (0.39) PNMTALDH1A1CYP1A2PYCR1CYP3A4
SCHEMBL4252113 0.72 PNMT (0.57) PNMTCYP1A2CYP2C9PYCR1DPP4
SCHEMBL1764819 0.72 ALDH1A1 (0.52) PNMTALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL30812547 0.70 ALDH1A1 (0.40) PNMTALDH1A1KDM4EGLAGAA
SCHEMBL3667293 0.69 PNMT (0.37) PNMTHPGDCYP1A2CYP2C9DPP4
SCHEMBL13816977 0.68 CYP3A4 (0.56) ALDH1A1KDM4EGAAHPGDCYP1A2
SCHEMBL20226102 0.68 PNMT (0.38) PNMTALDH1A1HPGDCYP1A2CYP2C9
SCHEMBL7873156 0.68 KMT2A (0.53) PNMTALDH1A1KDM4EGAAHPGD
SCHEMBL20196091 0.65 CYP1A2 (0.38) PNMTALDH1A1HPGDCYP1A2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190125753-A1 COMPOUNDS AND METHODS FOR INCREASING HEMATOPOIESIS UNIV SOUTHERN CALIFORNIA (US) 2019-05-02 US disclosed
WO-2017184808-A1 COMPOUNDS AND METHODS FOR INCREASING HEMATOPOIESIS UNIVERSITY OF SOUTHERN CALIFORNIA (US) 2017-10-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190125753-A1 COMPOUNDS AND METHODS FOR INCREASING HEMATOPOIESIS CTNNB1, CTNNA1, HCLS1 PNMT 4139/4885ALDH1A1 788/4885KDM4E 3927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.